![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
F. Hoffmann-La Roche Ltd Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary…